Skip to main content
Type at least 3 characters

2,501 articles

Original Research

Published on 22 Jan 2024

Cross-protection induced by highly conserved human B, CD4+, and CD8+ T-cell epitopes-based vaccine against severe infection, disease, and death caused by multiple SARS-CoV-2 variants of concern

in Vaccines and Molecular Therapeutics

  • Swayam Prakash
  • Nisha R. Dhanushkodi
  • Latifa Zayou
  • Izabela Coimbra Ibraim
  • Afshana Quadiri
  • Pierre Gregoire Coulon
  • Delia F. Tifrea
  • Berfin Suzer
  • Amin Mohammed Shaik
  • Amruth Chilukuri
Frontiers in Immunology
doi 10.3389/fimmu.2024.1328905
  • 13,680 views
  • 25 citations

Original Research

Published on 19 Jan 2024

Enhanced immunogenicity and protective efficacy in mice following a Zika DNA vaccine designed by modulation of membrane-anchoring regions and its association to adjuvants

in Vaccines and Molecular Therapeutics

  • Franciane Mouradian Emidio Teixeira
  • Luana de Mendonça Oliveira
  • Anna Cláudia Calvielli Castelo Branco
  • Ricardo Wesley Alberca
  • Emanuella Sarmento Alho de Sousa
  • Bruno Henrique de Sousa Leite
  • Wenny Camilla dos Santos Adan
  • Alberto JosĂ© da Silva Duarte
  • Roberto Dias Lins
  • Maria Notomi Sato
Frontiers in Immunology
doi 10.3389/fimmu.2024.1307546
  • 4,021 views
  • 1 citation

Original Research

Published on 17 Jan 2024

People who use drugs show no increase in pre-existing T-cell cross-reactivity toward SARS-CoV-2 but develop a normal polyfunctional T-cell response after standard mRNA vaccination

in Vaccines and Molecular Therapeutics

  • Murat Gainullin
  • Lorenzo Federico
  • Julie Røkke Osen
  • Viktoriia Chaban
  • Hassen Kared
  • Amin Alirezaylavasani
  • Fridtjof Lund-Johansen
  • Gull Wildendahl
  • Jon-Aksel Jacobsen
  • Hina Sarwar Anjum
Frontiers in Immunology
doi 10.3389/fimmu.2023.1235210
  • 3,330 views